02197 CLOVER BIOPHARMACEUTICALS LTD

Clover To Present at World Vaccine Congress Washington 2022

Clover To Present at World Vaccine Congress Washington 2022

SHANGHAI, China, April 12, 2022 (GLOBE NEWSWIRE) -- (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the The presentation will include data on SCB-2019 (CpG 1018/Alum), Clover’s adjuvanted protein-based COVID-19 vaccine candidate.

Presentation details are as follows:

 
Workshop Title:Vaccine Technology
Presenter:Igor Smolenov, SVP, Global Clinical Development, Clover Biopharmaceuticals
Presentation Title:Clover’s adjuvanted protein-based vaccine: efficacy against SARS-CoV-2 variants and duration of protection
Session Date and Time:April 18, 2022, 3:15 – 4:30 PM EST
Location:Meeting Level 4, Liberty Salon J

For more information or to register, visit the .  

About SCB-2019 (CpG 1018/Alum)

Employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2.

For more information, please visit Clover’s website:  and follow the company on .

Clover Biopharmaceuticals:

Cindy Min

SVP, Public Affairs

Naomi Eichenbaum

VP, Investor Relations





EN
12/04/2022

Underlying

02197CLOVER BIOPHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CLOVER BIOPHARMACEUTICALS LTD

 PRESS RELEASE
Free
02197 CLOVER BIOPHARM...

Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland Ch...

Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China --Clover launches AdimFlu-S (QIS) in mainland China, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older --  --Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile--  SHANGHAI, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the worl...

September 12, 2023 1 EN
 PRESS RELEASE
Free
02197 CLOVER BIOPHARM...

 三叶草生物四价季节性流感疫苗在中国大陆上市

 三叶草生物四价季节性流感疫苗在中国大陆上市 --三叶草生物四价季节性流感疫苗在中国大陆上市，这是国内目前唯一获批用于三岁及以上人群的进口四价季节性流感疫苗--  --第二个商业化产品强化了三叶草生物领先的呼吸道疫苗产品组合和财务可持续发展-- 中国上海, Sept. 12, 2023 (GLOBE NEWSWIRE) -- 致力以创新型疫苗拯救生命和改善全球健康水平的处于商业化阶段的全球生物制药公司——（以下简称“三叶草生物”；香港联交所股票代码：02197）今天宣布在中国大陆商业化上市四价季节性流感疫苗，这是国内目前唯一获批用于三岁及以上人群的进口四价季节性流感疫苗。目前，该疫苗已在中国26个省市准入，商业化准备充分。预计从2023年开始，该四价流感疫苗的销售额将增加三叶草生物的收益，并在2024年及以后贡献有意义的增长。 “我们的第二个商业化产品——四价季节性流感疫苗在中国大陆的上市——进一步强化了三叶草生物领先的呼吸道疫苗产品组合，有助于财务可持续发展，于未来贡献有意义的增长”，三叶草生物首席执行官兼执行董事梁果先生表示。“更重要的是，它有助于三叶草生物进一步在自费市场搭建商业化能力，而这将支持我们呼吸道疫苗产品管线协同发展。” 三叶草生物的四价季节性流感疫苗是一种可用于预防流感的四价裂解灭活疫苗。它含有源于四种流感病毒株（两种甲型和两种乙型）的血凝素，无...

September 12, 2023 1 EN
 PRESS RELEASE
Free
02197 CLOVER BIOPHARM...

Clover Provides Updates on Business and R&D Pipeline Development

Clover Provides Updates on Business and R&D Pipeline Development -- Clover’s leading respiratory vaccine franchise to be strengthened from commercial launch of quadrivalent influenza vaccine (AdimFlu-S [QIS]) in mainland China in H2-2023 -- -- Poised to be a leading RSV vaccine player in China with global potential by leveraging validated Trimer-Tag platform and GMP manufacturing capabilities -- -- Resilient cash balance of approximately RMB 1.5 billion as of June 30, 2023 compared to RMB 1.86 billion as of December 31, 2022, with approximately 50% reduction1 in operating expenditures ach...

July 10, 2023 1 EN
 PRESS RELEASE
Free
02197 CLOVER BIOPHARM...

三叶草生物商业化和研发管线的最新进展

三叶草生物商业化和研发管线的最新进展 --伴随2023年下半年四价季节性流感疫苗（AdimFlu-S [QIS]）在中国大陆的商业化，三叶草生物领先的呼吸道疫苗产品组合强势发力-- --利用已经验证的Trimer-Tag技术平台和GMP生产能力，三叶草生物有望成为中国领先的且具有全球潜力的呼吸道合胞病毒（RSV）疫苗厂商-- --截至2023年6月30日，充沛的现金余额约为15亿人民币，而截至2022年12月31日为18.6亿人民币，与2022年上半年相比，2023年上半年实现了约50%运营支出减少1；预计未来12个月内，将继续保持运营效率提高的趋势-- 中国上海, July 11, 2023 (GLOBE NEWSWIRE) -- 致力以创新型疫苗拯救生命和改善全球健康水平的处于商业化阶段的全球生物制药公司——（以下简称“三叶草生物”；香港联交所股票代码：02197）今天公布了商业化和研发管线的最新进展。 三叶草生物首席执行官兼执行董事梁果先生表示：“自2023年初以来，三叶草生物在建立领先的呼吸道疫苗产品组合方面取得了重大进展，增加了一个商业化阶段的四价季节性流感疫苗，并着力推进RSV疫苗，该疫苗正在利用已经验证的蛋白质三聚体化（Trimer-Tag）平台进行开发。同时，我们还采取了一些重大举措，例如通过疫苗销售获得营收、提高运营效率和保持弹性的现金状况等，以...

July 10, 2023 1 EN
 PRESS RELEASE
Free
02197 CLOVER BIOPHARM...

Clover Announces Corporate Updates and Full Year 2022 Financial Result...

Clover Announces Corporate Updates and Full Year 2022 Financial Results -- Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in 2023 with continued growth thereafter -- -- Clover’s COVID-19 vaccine now listed in 24 provinces and municipalities in China (representing >80% population coverage) and well-positioned to be a major player in upcoming vaccination campaigns; anticipated to receive emergency use authorization (EUA) and sign a bilateral supply agreement in at least one additional cou...

March 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch